LVDP 2P.2.EGFP
(Plasmid
#231905)
-
PurposeFor the production of SARS-CoV-2 virus-like particles (VLPs) in the '2-plasmid' system and packaging EGFP mRNA into the VLPs
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 231905 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepCSC-G
-
Vector typeLentiviral
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
Cloning Information
- Cloning method Other
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byJennifer Doudna, Plasmid GFP-PS9 (Addgene # 177944)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
LVDP 2P.2.EGFP was a gift from Sriram Neelamegham (Addgene plasmid # 231905 ; http://n2t.net/addgene:231905 ; RRID:Addgene_231905) -
For your References section:
Conserved role of spike S2 domain N-glycosylation across betacoronaviruses. Yang Q, Kelkar A, Manicassamy B, Neelamegham S. npj Viruses. 2025 Jan; 3(4). doi: 10.1038/s44298-024-00085-7. 10.1038/s44298-024-00085-7